Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Kudo R, et al. Among authors: chandarlapaty s. Cancer Cell. 2024 Nov 11;42(11):1983. doi: 10.1016/j.ccell.2024.10.013. Cancer Cell. 2024. PMID: 39532066 Free article. No abstract available.
APOBEC3 mutagenesis drives therapy resistance in breast cancer.
Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva EM, Brown DN, Zhu Y, Patel J, Blanco-Heredia J, Stefanovska B, Carpenter MA, Pei X, Frosina D, Jungbluth AA, Ladanyi M, Curigliano G, Weigelt B, Riaz N, Powell SN, Razavi P, Harris RS, Reis-Filho JS, Marra A, Chandarlapaty S. Gupta A, et al. Among authors: chandarlapaty s. bioRxiv [Preprint]. 2024 May 1:2024.04.29.591453. doi: 10.1101/2024.04.29.591453. bioRxiv. 2024. PMID: 38746158 Free PMC article. Preprint.
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.
Zucker M, Perry MA, Gould SI, Elkrief A, Safonov A, Thummalapalli R, Mehine M, Chakravarty D, Brannon AR, Ladanyi M, Razavi P, Donoghue MTA, Murciano-Goroff YR, Grigoriadis K, McGranahan N, Jamal-Hanjani M, Swanton C, Chen Y, Shen R, Chandarlapaty S, Solit DB, Schultz N, Berger MF, Chang J, Schoenfeld AJ, Sánchez-Rivera FJ, Reznik E, Bandlamudi C. Zucker M, et al. Among authors: chandarlapaty s. Cell. 2024 Dec 12:S0092-8674(24)01327-8. doi: 10.1016/j.cell.2024.11.010. Online ahead of print. Cell. 2024. PMID: 39701102 Free article.
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Green AK, Zhou Q, Iasonos A, Zammarrelli WA, Weigelt B, Ellenson LH, Chhetri-Long R, Shah P, Loh J, Hom V, Selenica P, Erinjeri J, Petkovska I, Chandarlapaty S, Cohen S, Grisham R, Konner J, Rubinstein MM, Tew W, Troso-Sandoval T, Aghajanian C, Makker V. Green AK, et al. Among authors: chandarlapaty s. Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. Online ahead of print. Clin Cancer Res. 2024. PMID: 39561275
EGFR-directed antibodies promote HER2 ADC internalization and efficacy.
Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, Rosiek E, Romin Y, Ghafourian N, Thyparambil S, Misale S, Park W, de Stanchina E, Janjigian YY, Yaeger R, Li BT, Chandarlapaty S. Gupta A, et al. Among authors: chandarlapaty s. Cell Rep Med. 2024 Nov 19;5(11):101792. doi: 10.1016/j.xcrm.2024.101792. Epub 2024 Oct 21. Cell Rep Med. 2024. PMID: 39437778 Free PMC article.
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Huerga Sanchez I, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Kudo R, et al. Among authors: chandarlapaty s. Cancer Cell. 2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. Epub 2024 Oct 10. Cancer Cell. 2024. PMID: 39393354 Free article.
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer.
Safonov A, Marra A, Bandlamudi C, O'Leary B, Wubbenhorst B, Ferraro E, Moiso E, Lee M, An J, Donoghue MTA, Will M, Pareja F, Nizialek E, Lukashchuk N, Sofianopoulou E, Liu Y, Huang X, Ahmed M, Mehine MM, Ross D, Mandelker D, Ladanyi M, Schultz N, Berger MF, Scaltriti M, Reis-Filho JS, Li BT, Offit K, Norton L, Shen R, Shah S, Maxwell KN, Couch F, Domchek SM, Solit DB, Nathanson KL, Robson ME, Turner NC, Chandarlapaty S, Razavi P. Safonov A, et al. Among authors: chandarlapaty s. bioRxiv [Preprint]. 2024 Aug 26:2024.02.05.578934. doi: 10.1101/2024.02.05.578934. bioRxiv. 2024. PMID: 39253462 Free PMC article. Preprint.
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Liu SY, Erazo T, Jee J, Arfe A, Gupta A, Pike LRG, Santini FC, Daly B, Schoenfeld A, Eichholz J, Johnson K, Martinez A, Sui J, Riaz N, Chang J, Yang SR, Travis W, Arcila ME, Guo J, Gagne E, Garg K, Baehner F, Lee NY, Drilon A, Kris MG, Scher HI, Razavi P, Gomez DR, Jones DR, Rudin CM, Chandarlapaty S, Isbell JM, Li BT. Liu SY, et al. Among authors: chandarlapaty s. Eur J Cancer. 2024 Oct;210:114257. doi: 10.1016/j.ejca.2024.114257. Epub 2024 Aug 14. Eur J Cancer. 2024. PMID: 39151324
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
Pareja F, Dopeso H, Wang YK, Gazzo AM, Brown DN, Banerjee M, Selenica P, Bernhard JH, Derakhshan F, da Silva EM, Colon-Cartagena L, Basili T, Marra A, Sue J, Ye Q, Da Cruz Paula A, Yeni Yildirim S, Pei X, Safonov A, Green H, Gill KY, Zhu Y, Lee MCH, Godrich RA, Casson A, Weigelt B, Riaz N, Wen HY, Brogi E, Mandelker DL, Hanna MG, Kunz JD, Rothrock B, Chandarlapaty S, Kanan C, Oakley J, Klimstra DS, Fuchs TJ, Reis-Filho JS. Pareja F, et al. Among authors: chandarlapaty s. Cancer Res. 2024 Oct 15;84(20):3478-3489. doi: 10.1158/0008-5472.CAN-24-1322. Cancer Res. 2024. PMID: 39106449
155 results